Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIM-004 topical gel with NB-UVB in adults with stable nonsegmental vitiligo
ISRCTN78313275Phase 2Terminated
- Sponsor
- Vimela Therapeutics
- Start
- Jan 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo and nonsegmental vitiligo comparing VIM-004 gel + NB-UVB with Placebo gel + NB-UVB (2 arms). Primary endpoints: Local tolerability and adverse events, Vital signs and physical examinations and 1 more. Started Jan 2025; status: terminated.
02
Drugs
afamelanotide
03
Conditions
Vitiligononsegmental vitiligo
Beyond the preview
Go deeper on ISRCTN78313275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78313275.